Current News - U.S.
- New Aptivus® (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
- PRoFESS® Results Announced at XVII European Stroke Conference
- Boehringer Ingelheim Committed to Advancing the Science of Hypoactive Sexual Desire Disorder
- Second Chances Study Shows Most Stroke Survivors “Very Satisfied” with their Overall Quality of Life
- Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population
- View more Current News : : View the News Archive
BI Spotlight
New Aptivus® (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
Ridgefield, CT - June 24, 2008 --
The U.S. Food and Drug Administration (FDA) granted approval of Aptivus® (tipranavir) capsules/oral solution for use in treatment-experienced pediatric patients between the ages of 2-18 infected with HIV-1.
Please see full Prescribing Information, including boxed warning for APTIVUS, at www.aptivus.com.
Product Sites
Job Openings
Our Locations
R&D
